FDA Advisory Panel Considers Trial Designs For Community Acquired Pneumonia
This article was originally published in The Pink Sheet Daily
Executive Summary
Non-inferiority margins in anti-infectives trials, product development topics on schedule for April meeting.
You may also be interested in...
Theravance Trims Loss, CEO “Optimistic” About FDA Panel Ahead
Feb. 27 brings first test of noninferiority’s importance to regulators, analyst tells “The Pink Sheet” DAILY.
Theravance Trims Loss, CEO “Optimistic” About FDA Panel Ahead
Feb. 27 brings first test of noninferiority’s importance to regulators, analyst tells “The Pink Sheet” DAILY.
FDA Anti-Infective Drugs Advisory Committee To Review Two Antibiotics
Johnson & Johnson’s ceftobiprole and Theravance’s telavancin will be discussed Feb. 27-28.